Escitalopram add-on in stable Schizophrenia with subsyndromal depression

Simple item page
dc.contributor.authorNischal, Anilen_US
dc.contributor.authorSingh, Poojaen_US
dc.contributor.authorAgarwal, Manuen_US
dc.contributor.authorNischal, Anuradhaen_US
dc.contributor.authorGupta, Bandnaen_US
dc.contributor.authorTripathi, Adarshen_US
dc.date.accessioned2020-04-09T07:43:28Z
dc.date.available2020-04-09T07:43:28Z
dc.date.issued2020-02
dc.description.abstractBackground: Significant proportion of the patients of schizophrenia suffer from subsyndromal symptomatic depressive symptoms (SSD) which not only add to the burden of disease but also to the already pre-existing challenges of living with this serious mental illness. Many psychiatrists prescribe antidepressants to patients with schizophrenia who have subsyndromal symptomatic depressive symptoms but data regarding SSD in schizophrenia is meagre. Aim was to study the effect of addition of Escitalopram on psychopathology, cognition and functioning in patients with stable schizophrenia having subsyndromal depressive symptoms and to compare these parameters with patients treated with antipsychotics alone.Methods: The study was a prospective, 8-week randomized double-blind placebo-controlled trial. Seventy four patients who fulfilled the diagnostic criteria of Schizophrenia on the basis of the ICD10-DCR, adjudged to be stable clinically and not requiring any increase in dose of antipsychotic medication over the last eight weeks were recruited into the study. The patients randomly received either Antipsychotics with add-on Escitalopram (10 mg/day) or Antipsychotics with placebo for 8 weeks. The patients were assessed using the HAM-D, CDRS, PANSS, SCoRS, SOFAS and CGI scores at the end of 8 weeks. Patients were also assessed for adverse events at baseline, week 4 and week 8.Results: A total of sixty-six patients who completed the study were analyzed. The HAM-D, CDRS and PANSS score showed significantly better cognition and functioning in the patients of add-on Escitalopram group when compared with the placebo group. There was no significant difference between the two groups in terms of observed side effects.Conclusions: Escitalopram addition to the standard anti-psychotic treatment of schizophrenia, in patients having subsyndromal depressive symptoms, results in better cognition and improved functioning.en_US
dc.identifier.affiliationsDepartment of Psychiatry, KGMU, Lucknow, Uttar Pradesh, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, KGMU, Lucknow, Uttar Pradesh, Indiaen_US
dc.identifier.citationNischal Anil, Singh Pooja, Agarwal Manu, Nischal Anuradha, Gupta Bandna, Tripathi Adarsh. Escitalopram add-on in stable Schizophrenia with subsyndromal depression. International Journal of Advances in Medicine. 2020 Feb; 7(2): 211-217en_US
dc.identifier.issn2349-3925
dc.identifier.issn2349-3933
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/194568
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber2en_US
dc.relation.volume7en_US
dc.source.urihttps://dx.doi.org/10.18203/2349-3933.ijam20196076en_US
dc.subjectEscitalopramen_US
dc.subjectSchizophreniaen_US
dc.subjectSubsyndromal depressionen_US
dc.titleEscitalopram add-on in stable Schizophrenia with subsyndromal depressionen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijam2020v7n2p211.pdf
Size:
324.43 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Advances in Medicine